Xinyu Zhao

Dr. Xinyu Zhao

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
JRJoel D. Richter
Joel D. Richter
XZXinyu Zhao
Xinyu Zhao

1 December 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
XZXinyu Zhao
Xinyu Zhao
Anita BhattacharyyaAnita Bhattacharyya
Anita Bhattacharyya

3 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJichao Sun
Jichao Sun
JCJared Carlson-Stevermer
Jared Carlson-Stevermer
UDUtpal Das
Utpal Das
MSMinjie Shen
Minjie Shen
MDMarion Delenclos
Marion Delenclos
SRSubhojit Roy
Subhojit Roy
CRISPR/Cas9 guided gene-editing is a potential therapeutic tool, however application to neurodegenerative disease models has been limited. Moreover, conventional mutation correction by gene-editing would only be relevant for the small fraction of neurodegenerative cases that are inherited. Here we introduce a CRISPR/Cas9-based strategy in cell and animal models to edit endogenous amyloid precursor protein (APP) at the extreme C-terminus and reciprocally manipulate the amyloid pathway, attenuating APP-β-cleavage and Aβ production, while up-regulating neuroprotective APP-α-cleavage. APP N-terminus and compensatory APP-homologues remain intact, with no apparent effects on neurophysiology in vitro. Robust APP-editing is seen in human iPSC-derived neurons and mouse brains with no detectable off-target effects. Our strategy likely works by limiting APP and BACE-1 approximation, and we also delineate mechanistic events that abrogates APP/BACE-1 convergence in this setting. Our work offers conceptual proof for a selective APP silencing strategy.

2 December 2017 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
XZXinyu Zhao
Xinyu Zhao
DMDarcie L. Moore
Darcie L. Moore

11 February 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MSMinjie Shen
Minjie Shen
FWFeifei Wang
Feifei Wang
MLMeng Li
Meng Li
NSNirnath Sah
Nirnath Sah
MSMichael E. Stockton
Michael E. Stockton
XZXinyu Zhao
Xinyu Zhao

29 October 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BLBotao Liu
Botao Liu
YLYue Li
Yue Li
ESEmily E. Stackpole
Emily E. Stackpole
ANAnnie Novak
Annie Novak
YGYu Gao
Yu Gao
JRJoel D. Richter
Joel D. Richter
Fragile X syndrome (FXS) is caused by the loss of fragile X mental retardation protein (FMRP), an RNA binding protein whose deficiency impacts many brain functions, including differentiation of adult neural stem cells (aNSCs). However, the mechanism by which FMRP influences these processes remains unclear. Here, we performed ribosome profiling and transcriptomic analysis of aNSCs in parallel from wild-type and Fmr1 knockout mice. Our data revealed diverse gene expression changes at both mRNA and translation levels. Many mitosis and neurogenesis genes were dysregulated primarily at the mRNA level, while numerous synaptic genes were mostly dysregulated at the translation level. Translational “buffering”, whereby changes in ribosome association with mRNA are compensated by alterations in RNA abundance, was also evident. Knockdown of NECDIN, an FMRP-repressed transcriptional factor, rescued neuronal differentiation. In addition, we discovered that FMRP regulates mitochondrial mRNA expression and energy homeostasis. Thus, FMRP controls diverse transcriptional and posttranscriptional gene expression programs critical for neural differentiation.